Table 1.

Relationship between APC2 methylation and clinicopathological parameters in CRC.

Clinical parameters	N (N1%)	Average methylation
		<0.2	≥0.2	p
Sex
Male	39 (59.1%)	26 (66.7%)	13 (33.3%)	0.037
Female	27 (40.9%)	11 (40.7%)	16 (59.3%)
Age (years)
<54	35 (53.0%)	19 (54.3%)	16 (45.7%)	0.758
≥54	31 (47.0%)	18 (58.1%)	13 (41.9%)
Performance status
0	2 (3.0%)	1 (50.0%)	1 (50.0%)	0.873
1	46 (69.7%)	25 (54.3%)	21 (45.7%)
2	18 (27.3%)	11 (61.1%)	7 (38.9%)
Tumor location
Ascending	17 (25.8%)	8 (47.1%)	9 (52.9%)	0.877
Transverse	6 (9.1%)	3 (50.0%)	3 (50.0%)
Descending	11 (16.7%)	6 (54.5%)	5 (45.5%)
Sigmoid	19 (28.8%)	12 (63.2%)	7 (36.8%)
Rectum	13 (19.7%)	8 (61.5%)	5 (38.5%)
Differentiation
High	0 (0.0%)	0 (0.0%)	0 (0.0%)	0.277
Moderate	36 (54.5%)	18 (50.0%)	18 (50.0%)
Low	30 (45.5%)	19 (63.3%)	11 (36.7%)
TNM
I	2 (3.0%)	1 (50.0%)	1 (50.0%)	0.681
II	14 (21.2%)	9 (64.3%)	5 (35.7%)
III	16 (24.2%)	7 (43.7%)	9 (56.3%)
IV	34 (51.5%)	20 (58.8%)	14 (41.2%)
T
1	2 (3.0%)	0 (0.0%)	2 (100.0%)	0.132
2	1 (1.5%)	1 (100.0%)	0 (0.0%)
3	36 (54.5%)	17 (47.2%)	19 (52.8%)
4	27 (41.0%)	18 (66.7%)	9 (33.3%)
N
0	21 (31.8%)	10 (47.6%)	11 (52.4%)	0.716
1	25 (37.9%)	14 (56.0%)	11 (44.0%)
2	20 (30.3%)	12 (60.0%)	8 (40.0%)
M
0	32 (48.5%)	16 (50.0%)	16 (50.0%)	0.472
1	34 (51.5%)	20 (58.8%)	14 (41.2%)
CEA (ng/ml)
0–4.9	21 (31.8%)	12 (57.1%)	9 (42.9%)	0.794
≥5	41 (62.1%)	22 (53.6%)	19 (46.4%)
NG	4 (6.1%)
Ki67
0–59	20 (30.3%)	9 (45.0%)	11 (55.0%)	0.308
≥60	39 (59.1%)	23 (59.0%)	16 (41.0%)
NG	7 (10.6%)
Fecal occult blood
Positive	40 (60.6%)	24 (60.0%)	16 (40.0%)	0.117
Negative	14 (21.2)%	5 (35.7%)	9 (64.3%)
NG	12 (18.2%)

Note: 0.2 is the median of the average methylation ratio; NG: not given.